Impact of clinical trial protocols on patient care systems at the University of Texas M.D. Anderson Cancer Center.
Clinical trial protocols represent a significant component of the research program at the University of Texas M.D. Anderson Cancer Center. Currently, there are nearly 800 active protocols using more than 150 investigational drugs. Sponsors of these trials include the National Cancer Institute, numerous pharmaceutical companies, and a variety of other funding sources. Because of our large patient base, however, routine participation in cooperative groups is limited. The impact of clinical trial protocols on patient care systems is a growing concern that is addressed primarily by the Surveillance Committee at M.D. Anderson. Like many institutional review boards, this committee reviews all protocols and must grant approval before the activation of any clinical trial. The issues of medical ethics, including a risk-benefit assessment for research subjects, equitable patient selection, safeguards for economically disadvantaged populations, and the general requirements for informed consent, also fall under the purview of this board. For any comprehensive cancer center to succeed, it must have strong research programs that enhance treatment options for patients. The crisis in financing health care significantly threatens the viability of cancer research. Reimbursement for the related costs of individuals participating in clinical trials has become a battle ground for third-party payers. The resulting economic risk is shared by health care providers and patients. As a consequence, many cancer centers, including M.D. Anderson, have initiated an economic-impact analysis for protocols as a component of the review process. This analysis includes an estimation of the patient care costs compared to the funding allocated to support the research. Future research will include pharmacoeconomic analysis and other ways to relate the costs and outcomes of treatment protocols. In the interim, we must monitor reimbursement trends for patients enrolled in clinical trials closely and amend the informed consent process to include a discussion of potential economic risk or hardship to patients if insurance claims are denied. Cancer care providers, third-party payers, the federal government, and society at large must work together to address the funding of cancer research and patient care.
Huber
S L
SL
Division of Pharmacy, University of Texas M.D. Anderson Cancer Center, Houston 77030.
D002173:Cancer Care Facilities / Q000191:economics*; D002986:Clinical Trials as Topic / Q000191:economics*; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006746:Hospital Bed Capacity, 500 and over; D006785:Hospitals, University / Q000191:economics*; D006801:Humans; D007349:Insurance, Health, Reimbursement; D009369:Neoplasms / Q000191:economics / Q000628:therapy*; D012109:Research Support as Topic; D013781:Texas